Pharmaceutical Development Expert Waldemar Lernhardt, PhD Joins GATC Health’s Advisory Board

IRVINE, Calif., June 30, 2022—GATC Health, a science and technology company revolutionizing drug discovery and disease prediction using artificial intelligence and advanced multiomics, is pleased to announce Waldemar Lernhardt, PhD, has joined its Board of Advisors. Dr. Lernhardt is highly experienced in pharmaceutical development including preclinical studies and clinical trial management. Dr. Lernhardt’s expertise will support the company’s existing preclinical research and help scale clinical development for the company’s future pipeline of de-novo drugs.

“We are extremely pleased to welcome Waldemar to our advisory board,” said Jeff Moses, President of GATC Health. “His deep experience in organizing development plans to move candidates from discovery and proof-of-concept studies through pre-clinical safety studies to regulatory standards to the clinic.”

Dr. Lernhardt has held Chief Executive Officer, Chief Science Officer and Chief Operating Officer positions at several biotech companies in the United States and Germany. His doctoral studies took place at the Basel Institute for Immunology, and he earned his PhD in immunology and biology/chemistry from Heidleberg University.

“I was very interested to work with GATC Health after learning how its platform has the power to discover and validate meaningful targets for new therapies and diagnostics that serve unmet clinical needs,” Dr. Lernhardt said. “The team members are highly motivated and enthusiastic, and I find their ‘we can do this’ attitude infectious. With my experience, I would like to support the company from its very successful path of discovery to the efficient transition to pharmaceutical/diagnostic products.”

To contact GATC Health: info@gatchealth.com • 833-333-GATC (4282)

About GATC HealthGATC Health Corp is a science and technology company using whole genome analysis and multiomics-based artificial intelligence to revolutionize disease detection and drug discovery. The company’s patented AI platform reduces risk, time and costs for life science companies by digitally reproducing the human body to find non-obvious answers to biology’s most complex questions. GATC Health is accelerating healthcare’s transition to predictive, individualized medicine.Disclaimer

The information set forth herein is presented for informational purposes only and should not be deemed an offer to sell securities.  This announcement contains information which the Company believes to be correct, including certain financial information and projections, but the Company does not guarantee as to the accuracy or completeness of such information.  The Company reserves the right to modify or amend the information contained herein.